All In Biotech

Drug Trial Radar · NCT05202262

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants With Inadequately Controlled Asthma (VATHOS).

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 645 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

645

Actual

Start

Jan 12, 2022

Primary completion

Feb 26, 2025

Study completion Feb 26, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.

Conditions

  • Asthma

Interventions

  • BFF MDI 320/9.6 μgDrug

    Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg

  • BFF MDI 160/9.6 μgDrug

    Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg

  • BD MDI 320 μgDrug

    Budesonide MDI (BD MDI), 320 μg

  • Open-label Symbicort TBH 320/9 μgDrug

    Open-label Symbicort Turbuhaler 320/9 μg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 24Time frame: At Week 24

Locations

142 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Fresno, California

  • Research Site

    Huntington Beach, California

  • Research Site

    La Palma, California

  • Research Site

    Lincoln, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Denver, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    Cutler Bay, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Peoria, Illinois

  • Research Site

    Lexington, Kentucky

  • Research Site

    White Marsh, Maryland

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Columbia, Missouri

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Kalispell, Montana

  • Research Site

    Missoula, Montana

  • Research Site

    Bellevue, Nebraska

  • Research Site

    Omaha, Nebraska

  • Research Site

    Henderson, Nevada

  • Research Site

    North Las Vegas, Nevada

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.